Safety and Efficacy of Kaletra in ARV Therapy Experienced Patients

Study Identifier
MEXI-P01-02
CT.gov Identifier
NCT00648999
EudraCT Identifier
Not available
EUCTIS ID
Not available
For general inquiries, please contact

844-663-3742 or [email protected]

Study Complete

Study Details

Medical Condition
  • Human Immunodeficiency Virus (HIV)
    • Study Drug
  • lopinavir/ritonavir
    • Phase
    Phase 4
    Sex
    Female & Male
    Age
    17+ years
    Inclusion and Exclusion Criteria
    Inclusion Criteria:
    * HIV Infected subjects * Subjects failing in current HIV treatment, or * Subjects with a viral load \< 400 copies/mL and not tolerating their current HIV treatment.
    Exclusion Criteria:
    * Subject is currently participating in another clinical study or has participated in another clinical study within 30 days prior to screening visit * Subject is pregnant

    Protocol Summary

    To demonstrate that patients treated with Kaletra have an improvement in their quality of life compared to the quality of life they had with their previous NRTI therapy.

    Study Locations

    Location
    Status
    Location
    Site Ref # / Investigator 4074
    León, Guanajauto, Mexico
    Status
    Not applicable
    Location
    Site Ref # / Investigator 4049
    Mexico City, Mexico City, Mexico, 01030
    Status
    Not applicable
    Location
    Site Ref # / Investigator 4050
    Mexico City, Mexico City, Mexico, 01120
    Status
    Not applicable
    Location
    Site Ref # / Investigator 4051
    Mexico City, Mexico City, Mexico, 09220
    Status
    Not applicable
    Location
    Site Ref # / Investigator 4077
    Mexico City, Mexico City, Mexico, 10300
    Status
    Not applicable
    Location
    Site Ref # / Investigator 4056
    Mexico City, Mexico City, Mexico
    Status
    Not applicable
    Showing {first} - {last} of {total} Results